Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opsens Inc V.OPS


Primary Symbol: T.OPS

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that can be integrated into other medical devices. The Industrial segment develops, manufactures and installs fiber optic sensing solutions for critical and demanding industrial applications. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and lesions access. It is approved for sale in the United States, European Union, Japan and Canada.


TSX:OPS - Post by User

Post by bossuon Oct 10, 2023 11:16am
149 Views
Post# 35677048

About Haemonetics...

About Haemonetics...A solid Company 
Haemonetics Reports Fourth Quarter and Fiscal 2023 Results; Provides Fiscal 2024 Guidance Boston, MA, May 11, 2023 - Haemonetics Corporation (NYSE: HAE) reported financial results for its fourth quarter and fiscal 2023, which ended April 1, 2023: 4th Quarter 2023 Fiscal 2023 Revenue, increase $304 million, 15% $1.169 billion, 18% Organic1 revenue increase 17% 21% Earnings per diluted share $0.57 $2.24 Adjusted earnings per diluted share $0.77 $3.03 Cash flow from operating activities $80 million $273 million Free cash flow before restructuring and restructuring related costs $71 million $190 million 1Excludes the impact of currency fluctuation and strategic exits of product lines. Chris Simon, Haemonetics’ CEO, stated: “Our consistently strong results throughout our fiscal year reflect significant progress in accelerating our transformational growth. We are outperforming in a challenging economic environment and meeting the needs of our customers while positioning us for future growth and success.”

What about  another ''BID''  at $ 3,50 or more in the coming weeks,?

Just be patient  for a higher bid for an extra 25 % premium !
<< Previous
Bullboard Posts
Next >>